QIAGEN Cancer Research Online Events

QIAGEN Cancer Research Online Events are webinars and online discussions for cancer researchers. Join our talks about cancer genomics, liquid biopsy or RNA biomarker discovery. Get access to recordings and presentations from our past events.

cfDNA variants and matched CTC gDNA variants: Is it possible and worth analyzing both?

Corinna Keup, Ph.D., University Hospital of Essen, Germany

Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, analysis of cfDNA and CTC in an “all from one tube” format is desired. Corinna presents a targeted DNA-seq workflow for CTC gDNA and cfDNA evaluation from the same blood sample and elucidates the value of cfDNA and CTC variants by comparing variants.

Digital PCR mutation assays with Locked Nucleic Acid technology for rare target detection

Michael Bussmann, QIAGEN

Identifying residual cancer below current detection levels, or monitoring rare drug-resistance mutations? Learn with Michael about QIAGEN´s new dPCR LNA Mutation Assays for detecting rare mutations on the new QIAcuity Nanoplate dPCR Instrument.

Preanalytical considerations and workflow solutions for liquid biopsies specimen

Tomasz Krenz, Ph.D., QIAGEN

In the field of liquid biopsy, there is an urgent need to standardize workflows to improve specimen quality and reduce diagnostic errors.Tomasz presents international initiatives and requirements to standardize preanalytical workflows, and  integrated solutions for liquid biopsy collection, preservation and nucleic acid purification for downstream analyses.
CTCs and their value in multimodality liquid biopsies analysis

Siegfried Hauch, QIAGEN

Circulating tumor cells, cell-free DNA (cfDNA) and extracellular vesicles – what can we learn when analyzing all of these from one blood sample? Discuss with Siegfried the value of multimodality liquid biopsy testing and the findings from a condensed workflow for multiple analyte extraction and analysis from one blood sample.

QIAseq Targeted Methyl Panels – A liquid biopsy-compatible solution for detection of methyl markers in NGS

Brian Dugan, QIAGEN

The analysis of tumor-associated differential cell-free DNA methylation has emerged as a promising biomarker for early detection, prognosis and real-time follow-up of tumor dynamics. Brian introduces new QIAseq Targeted Methyl Panels which deliver a novel, highly sensitive solution to determine methylation status from the most challenging sample types.

Microfluidic based nanoplate technology to overcome challenges in digital PCR

Gerald Schock, QIAGEN

Join the TechTalk about QIAGEN’s new digital PCR systems for improved precision in target quantification.

icon-cancer
Would you like to get broad awareness of your research?
Give a talk at an upcoming QIAGEN Cancer Research Online Event
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm